B+
Bull case
20%
Probability
Target price
$0.95
+77.5% vs current
BEAT
HeartBeamANasdaq / Health Care Equipment & Services
Last Price
At close
2026-07-23
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$0.65
+21.5% vs current
B-
Bear case
30%
Probability
Target price
$0.30
-43.9% vs current
AI sentiment snapshot
Latest data as of 2026-07-18
Recent news sentiment (30D)
+30.0
Positive
Company
-
Unavailable
Macro
+30.0
Positive
Pulse
-
Unavailable
Sentiment proxy
+58.3
Score
AI commentary
Issuer-driven news flow has been active and mostly constructive around the June strategic shift and ahead-of-schedule ALIGN-ACS enrollment. However, social coverage is unavailable, analyst revisions are not reliable, and post-news price attribution is unavailable. The Nasdaq notice and unproven commercialization model keep this a cautious monitoring view.
RankAlpha Sentiment Codex - 2026-07-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-16eventALIGN-ACS pilot data and FDA-path clarificationHigh impact
HeartBeam completed enrollment of 120 patients ahead of schedule. Data analysis is underway, with results expected at a cardiology conference and intended to inform a U.S. pivotal study and potential expanded FDA indication [#IR-2026-06-30].
2026-10-16eventQ2 strategy updateHigh impact
Management said it will provide more detail on the licensing-led commercialization strategy during the second-quarter 2026 conference call in August [#IR-2026-06-24].
2026-12-28catalystNasdaq minimum-bid compliance overhangHigh impact
HeartBeam received a Nasdaq deficiency notice after 30 consecutive business days below the $1.00 bid requirement. It has until December 28, 2026 to regain compliance; failure could lead to delisting proceedings [#SEC-8K-2026-07-02].
Recommendation
N/A
No formal recommendation provided.
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology